ResearcherMayo ClinicNo recent work listed

Isaac P. Horn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-2194-6272; OpenAlex author ID A5023933249. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2021: 1 paper

Papers 1

A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition. Co-author DOI 10.1016/j.jbc.2021.100634 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hu Li · 1 shared paper, 2021 · strength 0.10
- Paper A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhib… DOI 10.1016/j.jbc.2021.100634 ↗
Renzo Emanuel Vera · 1 shared paper, 2021 · strength 0.10
- Paper A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhib… DOI 10.1016/j.jbc.2021.100634 ↗
Kari G. Rabe · 1 shared paper, 2021 · strength 0.10
- Paper A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhib… DOI 10.1016/j.jbc.2021.100634 ↗
Gloria M. Petersen · 1 shared paper, 2021 · strength 0.10
- Paper A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhib… DOI 10.1016/j.jbc.2021.100634 ↗
Hugues Sicotte · 1 shared paper, 2021 · strength 0.10
- Paper A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhib… DOI 10.1016/j.jbc.2021.100634 ↗
Martín E. Fernández-Zapico · 1 shared paper, 2021 · strength 0.10
- Paper A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhib… DOI 10.1016/j.jbc.2021.100634 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.